celf2 Antibody

What is CELF2 and what cellular functions does it regulate?

CELF2 is an RNA-binding protein implicated in several post-transcriptional regulatory events. It plays critical roles in pre-mRNA alternative splicing, mRNA translation, and stability regulation. CELF2 functions by mediating exon inclusion and/or exclusion in pre-mRNAs subject to tissue-specific and developmentally regulated alternative splicing . Notably, CELF2 can function as both an activator and repressor of splicing, promoting inclusion of some exons while excluding others depending on the context . Recent research has also revealed CELF2's significant role in alternative polyadenylation (APA), where it competes with core polyadenylation machinery components to regulate 3' UTR identity . Additionally, CELF2 may function as a specific regulator of miRNA biogenesis by binding to primary microRNAs such as pri-MIR140 .

The multifaceted functionality of CELF2 necessitates careful selection of antibodies that target the appropriate epitopes for specific research questions. For instance, when studying CELF2's role in splicing regulation, antibodies recognizing RNA-binding domains would be most appropriate, while investigations of CELF2's protein-protein interactions might benefit from antibodies targeting other functional domains.

How does CELF2 expression vary across developmental contexts and cellular activation states?

CELF2 expression exhibits distinct tissue-specific and developmental patterns that directly impact its regulatory functions. In cardiac tissue, CELF2 expression decreases during development, whereas in T cells, CELF2 expression increases during both development and in response to antigen-induced signaling events .

When selecting antibodies for developmental studies, researchers should consider antibodies validated across different developmental stages of their target tissue, as epitope accessibility may vary with developmental changes in protein complexes or post-translational modifications.

What specific RNA sequences does CELF2 bind to and how can this inform experimental design?

CELF2 exhibits preferential binding to specific RNA sequence motifs, which is critical knowledge for designing RNA-protein interaction studies. Based on multiple studies, CELF2 preferentially binds to:

• UG-rich sequences

• UG repeat motifs

• UGUU motifs

• AU-rich sequences, particularly in the 3'-UTR of target mRNAs like COX2

• (CUG)n triplet repeats in the 3'-UTR of transcripts such as DMPK

When designing RNA constructs for CELF2 binding studies, researchers should incorporate these motifs to ensure robust interactions. For example, one study demonstrated successful UV crosslinking using recombinant CELF2 protein and an RNA corresponding to a polyadenylation site (PAS2) with approximately 85 nucleotides of upstream and downstream sequence . This experimental design allowed researchers to demonstrate how CELF2 competes with polyadenylation machinery proteins for binding to specific RNA sequences.

How are CELF2 antibodies optimally utilized in CLIP-Seq experiments?

CLIP-Seq (Crosslinking Immunoprecipitation followed by high-throughput sequencing) has emerged as a powerful technique for mapping CELF2-RNA interactions at the transcriptome-wide level. Based on published protocols, an optimized CLIP-Seq methodology for CELF2 involves:

• Cell preparation: Isolate biological replicate samples of cells maintained in appropriate conditions (e.g., Jurkat cells cultured with or without PMA stimulation)

• Crosslinking: Treat living cells with UV light to induce covalent crosslinks between CELF2 and directly bound RNA targets

• Cell lysis and RNA fragmentation: Fragment RNA to a size range of 30-110 nucleotides to facilitate precise mapping of binding sites

• Immunoprecipitation: Use a well-characterized antibody specific for endogenous human CELF2 to stringently purify CELF2-RNA complexes

• RNA isolation and sequencing: Release RNAs from the protein, tag with RNA linkers, and subject to high-throughput sequencing

Critical considerations include antibody specificity validation to ensure no appreciable cross-contamination from other RNA-binding proteins that recognize similar sequence motifs, such as CELF1, PTB, TIA1, or HuR . In published studies, researchers have confirmed that their CELF2 antibody efficiently precipitated all detectable CELF2 without cross-reactivity with these related proteins .

What validation steps are essential before using CELF2 antibodies in immunoprecipitation experiments?

Before employing CELF2 antibodies in immunoprecipitation experiments, researchers should perform the following validation steps:

• Western blot characterization: Confirm the antibody recognizes CELF2 at the expected molecular weight with minimal non-specific bands

• Cross-reactivity assessment: Test for potential cross-reactivity with closely related family members, particularly CELF1, which shares sequence homology with CELF2

• Immunoprecipitation efficiency: Validate that the antibody can efficiently deplete CELF2 from cell lysates, as demonstrated in published studies where the antibody "efficiently precipitated all detectable CELF2"

• Background binding control: Perform parallel immunoprecipitations with non-specific IgG to establish background binding levels

• RNA-binding specificity: For RNA immunoprecipitation applications, confirm binding to known CELF2 target sequences, such as UG-rich or AU-rich elements

One validated approach involved using specific antibodies in UV crosslinking experiments followed by immunoprecipitation to confirm the identity of CELF2 bound to RNA substrates containing downstream sequence elements (DSE) . This experiment revealed enhanced CELF2 binding to RNAs containing the DSE upon cellular stimulation, while RNAs with only upstream sequence elements (USE) exhibited minimal CELF2 association .

How can CELF2 antibodies be used to investigate the relationship between CELF2 and the polyadenylation machinery?

CELF2 antibodies can be instrumental in elucidating the competitive interactions between CELF2 and components of the polyadenylation machinery. A methodical approach involves:

• Preparing RNA constructs containing polyadenylation sites (PAS) of interest with upstream and downstream regulatory sequences

• Performing UV crosslinking experiments with recombinant CELF2 and polyadenylation factors such as CFIm25 and CstF64, both individually and in combination

• Using CELF2 antibodies in immunoprecipitation assays to isolate and identify CELF2-RNA complexes

• Analyzing how CELF2 affects binding of polyadenylation factors in dose-dependent competition experiments

This approach has revealed that CELF2 can inhibit the binding of polyadenylation factors like CFIm25 and CstF64 in a dose-dependent manner, with a concomitant increase in CELF2 binding to the RNA substrate . This evidence supports the model where CELF2 competes with core polyadenylation machinery components for binding to RNA sequences surrounding polyadenylation sites, thereby regulating alternative polyadenylation events.

How does CELF2 regulate alternative splicing in a position-dependent manner?

CELF2 exhibits position-dependent activity in regulating alternative splicing, a critical concept for researchers designing splicing reporter constructs or analyzing CELF2 binding patterns. Analysis of CLIP-Seq data compared with known functional targets reveals:

• CELF2 binding upstream of alternative exons generally promotes exon exclusion

• CELF2 binding downstream of alternative exons typically promotes exon inclusion

• CELF2 binding within exons can either enhance or suppress exon inclusion depending on context

This position-dependent functionality has been consistently observed across different cellular contexts, including heart, brain, and T cells . Strikingly, this general position-dependence is sufficient to explain the bi-directional activity of CELF2 on multiple T cell targets .

When designing experiments to study CELF2's impact on specific splicing events, researchers should map potential CELF2 binding sites relative to alternative exons and consider how the position of these sites might influence splicing outcomes.

What is the mechanism of CELF2 autoregulation through alternative polyadenylation?

CELF2 exhibits a fascinating self-regulatory mechanism through alternative polyadenylation of its own mRNA, which researchers can study using CELF2 antibodies in the following experimental approaches:

• CLIP-seq analysis reveals extensive binding of CELF2 protein within its own 3' UTR

• Upon stimulation (e.g., with PMA in Jurkat cells), both the retention of an intron and use of competing polyadenylation sites (PAS2 versus PAS3) in the CELF2 3' UTR are altered

• Direct UV crosslinking experiments demonstrate that CELF2 inhibits binding of polyadenylation factors CFIm25 and CstF64 around its own PAS2 site in a dose-dependent manner

• This competition mechanism allows CELF2 to regulate its own mRNA processing, contributing to the significant increase in CELF2 protein expression through both transcriptional and post-transcriptional mechanisms

This autoregulatory mechanism represents an elegant example of how RNA-binding proteins can control their own expression, creating feedback loops that fine-tune protein levels in response to cellular signals.

What experimental approaches can reveal CELF2-dependent splicing events in T cells?

To identify CELF2-dependent splicing events in T cells, researchers have successfully employed the following experimental strategy:

• CELF2 depletion: Use RNA interference to deplete CELF2 in T cells (e.g., Jurkat cells)

• Cellular stimulation: Treat both control and CELF2-depleted cells with an appropriate stimulus (e.g., PMA)

• Splicing analysis: Use high-throughput approaches like RASL-Seq to identify alternative splicing events that respond to stimulation

• CELF2 dependency assessment: Compare splicing patterns between control and CELF2-depleted cells to identify events whose regulation depends on CELF2

Using this approach, researchers identified approximately 200 exons that significantly changed inclusion (>10 percentage points) upon PMA stimulation of wild-type Jurkat cells . Strikingly, for about one-third of these stimulation-responsive exons (72 of 200), CELF2 depletion reduced the PMA-induced change in inclusion by over 60% . This indicates that CELF2 is a major driver of signal-responsive splicing in T cells.

The table below summarizes key findings from CELF2-dependent splicing analyses:

How is CELF2 expression regulated during T-cell activation and development?

CELF2 expression in T cells is regulated through multiple mechanisms during both activation and development:

This multilayered regulation suggests that precise control of CELF2 levels is critical for proper T-cell development and function. Researchers investigating CELF2 in immune contexts should consider both transcriptional and post-transcriptional regulatory mechanisms when interpreting changes in CELF2 expression.

How does CELF2 contribute to splicing regulation during thymic T-cell development?

CELF2 plays a significant role in shaping the splicing landscape during thymic T-cell development, as evidenced by:

• Correlation of increased CELF2 expression with splicing changes: CELF2 expression increases during the transition from double-negative (DN) to double-positive (DP) thymocytes, coinciding with specific splicing changes

• Shared CELF2-dependent events between activation and development: Several exons regulated by CELF2 during T-cell activation in Jurkat cells also show developmental regulation in the thymus

• Validation of CELF2 dependence: Experimental depletion of CELF2 in Jurkat cells alters splicing in a pattern opposite to that observed during the DN to DP transition, consistent with increased CELF2 expression in DP cells driving developmental splicing changes

Remarkably, RASL-Seq analysis of human thymic samples identified 14 exons with significant splicing changes during development, and 4 of these events (29%) were among the 72 CELF2-dependent signal-responsive exons identified in Jurkat cells (p<0.00036) . This statistically significant overlap strongly supports the role of CELF2 in regulating splicing during thymic development.

What specific genes undergo CELF2-dependent alternative splicing in T cells?

CELF2 regulates the alternative splicing of numerous genes critical for T-cell biology. While the complete list of targets is extensive, some notable CELF2-dependent alternatively spliced genes include:

• SRPK2: Shows CELF2-dependent splicing changes both during T-cell activation and thymic development

• CTTN, OPA1, MPRL42: Exhibit CELF2-dependent splicing in Jurkat cells and corresponding changes during thymic development

• LEF1: Previous studies demonstrated CELF2-dependent regulation

For 42 of the 72 CELF2-dependent signal-responsive exons identified, CELF2 depletion has minimal effect (<10%) on inclusion in resting cells . This suggests that the low baseline expression of CELF2 in resting cells is insufficient to alter splicing of these genes, but the signal-induced increase in CELF2 expression drives their responsive splicing.

When studying these CELF2-dependent events, researchers should consider both the direct binding of CELF2 to pre-mRNAs and the position-dependent effects of such binding on splicing outcomes.

What are critical parameters for UV crosslinking experiments with CELF2 antibodies?

UV crosslinking is a fundamental technique for studying CELF2-RNA interactions. For optimal results, researchers should consider:

• Crosslinking conditions: UV irradiation of living cells creates covalent bonds between CELF2 and directly bound RNA molecules, preserving in vivo interactions

• RNA fragmentation: Fragment RNA to 30-110 nucleotides for optimal resolution of binding sites while maintaining sufficient context

• Protein concentration: When studying competition between CELF2 and other RNA-binding proteins, carefully titrate protein concentrations to observe dose-dependent effects

• RNA substrate design: Include relevant binding motifs (UG-rich or AU-rich sequences) and sufficient flanking sequence (~85 nucleotides upstream and downstream of sites of interest)

• Specificity controls: Include negative controls lacking known binding motifs to confirm binding specificity

In competition experiments, researchers have successfully demonstrated that CELF2 can inhibit binding of polyadenylation factors CFIm25 and CstF64 to RNA substrates in a dose-dependent manner . Such experiments require careful optimization of protein-to-RNA ratios to observe the competitive interactions effectively.

How can researchers distinguish CELF2-specific effects from those of other CELF family proteins?

Distinguishing CELF2-specific effects from those of related family members requires careful experimental design:

• Antibody specificity: Use antibodies validated for lack of cross-reactivity with other CELF family proteins, particularly CELF1, which shares structural similarities

• Immunoprecipitation validation: Confirm that immunoprecipitation with CELF2 antibodies does not co-precipitate other RNA-binding proteins that recognize similar sequence motifs (CELF1, PTB, TIA1, HuR)

• Depletion specificity: When using RNA interference to deplete CELF2, verify that expression of other CELF family members remains unchanged

• Rescue experiments: Validate CELF2-specific effects by rescuing phenotypes through expression of an RNAi-resistant CELF2 construct

• Binding motif analysis: Compare binding preferences of CELF2 with other family members through in vitro binding assays with different RNA motifs

These approaches help ensure that observed effects on splicing or other RNA processing events can be specifically attributed to CELF2 rather than other related RNA-binding proteins.

What storage and handling conditions are optimal for maintaining CELF2 antibody performance?

For optimal performance and longevity of CELF2 antibodies, researchers should follow these storage and handling guidelines:

• Short-term storage: Store at 4°C for immediate use or ongoing experiments

• Long-term storage: Aliquot and store at -20°C to maintain antibody stability

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles that can degrade antibody quality

• Buffer composition: Commercial CELF2 antibodies may be supplied in buffers containing:

  • 50mM Tris-Glycine (pH 7.4)

  • 0.15M NaCl

  • 40% Glycerol

  • 0.01% Sodium azide

  • 0.05% BSA

• Working dilutions: Prepare fresh working dilutions for each experiment rather than storing diluted antibody for extended periods

Proper storage and handling of CELF2 antibodies ensures consistent performance across experiments and maximizes the value of these critical research reagents.